New drug shows promise for Hard-to-Treat cancers
NCT ID NCT05631262
First seen Feb 15, 2026 · Last updated Jun 12, 2026 · Updated 23 times
Summary
This study tests a new drug called SKB264 in people with advanced solid tumors (like lung or nasopharyngeal cancer) that have not responded to other treatments. The goal is to see if the drug can shrink tumors and how safe it is. Participants receive the drug until it stops working or side effects become too severe.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SELECTED SUBJECTS WITH ADVANCED SOLID TUMORS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.